Physician profile
Jayant Uberoi
NPI 1912176702
$20,080.77
in general payments reported to CMS, 2019-2025
57 companies · $2,653 in 2025
The $2,653 reported for 2025 was more than what 85% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,953 · 2020: $524 · 2021: $2,212 · 2022: $3,789 · 2023: $5,588 · 2024: $2,362 · 2025: $2,653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,810 · Travel and Lodging: $1,673 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112 · Education: $8.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,809.89 |
| Travel and Lodging | $1,673.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111.79 |
| Education | $8.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $3,082.93 | 2021-2025 | Urolift |
| Sn Holdings, LLC | $2,380.00 | 2023 | |
| Neotract INC. | $1,443.16 | 2019 | |
| Sumitomo Pharma America, INC. | $1,337.13 | 2023-2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $1,057.72 | 2019-2025 | Botox |
| Janssen Biotech, INC. | $776.76 | 2019-2025 | Erleada, Akeega, Balversa |
| Bayer Healthcare Pharmaceuticals INC. | $760.40 | 2019-2025 | |
| Pfizer INC. | $756.50 | 2019-2025 | |
| Astellas Pharma US INC | $736.67 | 2019-2023 | Myrbetriq, Xtandi |
| Antares Pharma, INC. | $647.15 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Urovant Sciences INC | $645.52 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $466.32 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $459.93 | 2019-2025 | Provenge |
| Endo Pharmaceuticals INC. | $457.32 | 2019-2024 | Xiaflex, Aveed |
| Progenics Pharmaceuticals, INC. | $425.36 | 2021-2025 | Pylarify |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $412.64 | 2023-2025 | Jatenzo, Eligard |
| Allergan, INC. | $394.78 | 2019-2022 | |
| Boston Scientific Corporation | $365.75 | 2021-2025 | Spaceoar Vue System - 10ml, Ams 800 Artificial Urinary Sphincter, Rezum Generator |
| Olympus America INC. | $344.79 | 2021-2025 | Itind System |
| Urogen Pharma, INC. | $259.21 | 2021-2025 | |
| Ferring Pharmaceuticals INC. | $250.25 | 2019-2024 | Adstiladrin |
| Amgen INC. | $200.14 | 2019-2023 | Xgeva |
| Medtronic, INC. | $182.92 | 2022-2023 | Interstim |
| Immunitybio, INC. | $160.04 | 2025 | |
| Procept Biorobotics Corporation | $156.68 | 2021 | |
| Janssen Scientific Affairs, LLC | $150.11 | 2019-2021 | |
| Myovant Sciences INC. | $147.24 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $146.01 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Endo USA, INC. | $138.86 | 2024-2025 | Xiaflex, Aveed |
| Novartis Pharmaceuticals Corporation | $135.24 | 2025 | |
| Myriad Genetic Laboratories, INC. | $131.99 | 2021-2022 | |
| 180 Medical, INC. | $122.56 | 2019-2024 | |
| Renovia INC | $90.89 | 2020 | |
| Blue Earth Diagnostics | $88.40 | 2019-2025 | Posluma |
| C. R. Bard, INC. & Subsidiaries | $74.97 | 2019-2023 | Bard Urinary Drainage Bag |
| Clarus Therapeutics INC. | $65.80 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $60.51 | 2025 | |
| Rochester Medical Corporation | $59.19 | 2021 | |
| Halozyme INC | $59.01 | 2023 | |
| Accord Healthcare, INC. | $57.05 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $44.95 | 2021-2024 | Lynparza |
| Convatec INC. | $42.15 | 2021-2022 | |
| Abc Home Medical Supply, INC. | $37.87 | 2024-2025 | |
| Caris Mpi, INC. | $35.81 | 2025 | Mi Cancer Seek |
| Dentsply Ih INC. | $31.23 | 2022 | |
| Photocure INC | $28.57 | 2019-2025 | Cysview |
| Coloplast Corp | $26.40 | 2024 | |
| Cook Medical LLC | $21.59 | 2025 | Litho 150 |
| Foundation Medicine, INC. | $20.50 | 2023 | Foundationone Liquid Cdx |
| Zyla Life Sciences, INC. | $16.67 | 2019 | |
| Tempus Ai, INC | $15.96 | 2024 | Xt Cdx |
| Hollister Incorporated | $15.95 | 2023 | Vapro, Infyna Chic |
| Acerus Pharmaceuticals Corporation | $14.88 | 2022 | |
| Profound Medical Corp. | $14.22 | 2025 | Tulsa-Pro |
| Metuchen Pharmaceuticals | $14.14 | 2019 | |
| Clovis Oncology, INC. | $11.98 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$361,837.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayant Uberoi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.